Regencell Bioscience Holdings Limited Announces Pricing of Approximately $21.9 Million Initial Public Offering
Regencell Bioscience Holdings Limited (NASDAQ:RGC) (Regencell or the Company), an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD), today announced the pricing of its initial public offering (Offering) of 2,300,000 ordinary shares at a public offering price of $9.50 per ordinary share.
- Regencell Bioscience Holdings Limited (NASDAQ:RGC) (Regencell or the Company), an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD), today announced the pricing of its initial public offering (Offering) of 2,300,000 ordinary shares at a public offering price of $9.50 per ordinary share.
- Regencell expects to receive aggregate gross proceeds of approximately $21.9 million from this Offering, before deducting underwriting discounts and other related expenses.
- The Offering is expected to close on or about July 20, 2021, subject to the satisfaction of customary closing conditions.
- Regencell Bioscience Holdings Limited is an early-stage bioscience company that focuses on research, development and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, specifically ADHD and ASD.